热门资讯> 正文
INVO BioScience报告第四季度业绩
2024-04-17 05:17
- INVO BioScience press release (NASDAQ:INVO): Q4 Revenue of $1.38M (+392.9% Y/Y) misses by $0.55M.
- Net loss was $(2.0) million, compared to $(2.8) million.
- Adjusted EBITDA was $(1.2) million, including transaction costs related to the potential merger, compared to $(2.2) million in the prior year.
More on INVO BioScience
- NAYA Biosciences to buy gene therapy company Florida Biotechnologies
- Seeking Alpha’s Quant Rating on INVO BioScience
- Historical earnings data for INVO BioScience
- Financial information for INVO BioScience
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
